Analyst consensus rating

Seres Therapeutics Analyst Rating: none

Direct answer

Seres Therapeutics's consensus rating is none.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked November 21, 2026.

Get free Seres Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$1.24
Average price target
$17.00
High price target
$22.00
Low price target
$12.00
Low target gap
+867.7%
Target upside
+1,271%
High target gap
+1,674.2%
Target range width
806.5%
Consensus rating
none
Analysts
2
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Seres Therapeutics?

Seres Therapeutics has a verified none consensus. The same dataset has an average price target of $17.00.

How far are Seres Therapeutics's low and high targets from the recorded price?

The low target implies +867.7%, while the high target implies +1,674.2%.

How many analysts are included in Seres Therapeutics's consensus?

The verified consensus includes 2 analysts.

How is Seres Therapeutics's target upside or downside calculated?

The average target of $17.00 is divided by the recorded price of $1.24, then one is subtracted to produce +1,271%. This does not guarantee a future return.

When was Seres Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.